Analysis of Micro and Nanoplastics and Engineered Nanoparticles in Human Placenta / MiNaPla

Objectives
- Develop and establish validated analytical workflows for detecting, quantifying and characterizing microplastics, nanoplastics and engineered metal-based nanoparticles in human placenta and blood
- Enable reliable analysis at the low particle concentrations expected in real-world human samples
- Control contamination, particle recovery and potential particle transformation during sampling, sample preparation and measurement
- Investigate the co-existence of plastics and metals and assess a possible Trojan-horse effect in human biological samples
Methods of Approach
- Raman Microspectroscopy (RM) → Polymer identification and particle characterization
- TUM-ParticleTyper 2 → Automated particle detection, image analysis and spectral assignment
- Field-Flow Fractionation (FFF) → Separation and analysis of small particles and size fractions
- Online FFF-Raman → Size resolved physicochemical characterization
- Scanning Electron Microscopy (SEM) → High-resolution morphology and elemental analysis
- Single-particle ICP-MS → Detection, sizing and quantification of metal-based nanoparticles
- Trace-element analysis → Characterization of metals in placenta and blood
Description
Human exposure to particulate anthropogenic pollutants is increasing, while reliable information on their presence and amount in the placenta remains scarce, especially for small microplastics and nanoplastics.
The placenta is the essential interface between mother and foetus. Although it acts as a highly effective barrier, particles in the micrometre and nanometre range may cross biological barriers and reach placental or foetal tissue. Microplastics, nanoplastics and engineered metal-based nanoparticles are therefore emerging contaminants of particular relevance to prenatal exposure and development.
Existing studies indicate that plastic particles can occur in human placenta, but comparison and risk assessment are limited by the lack of validated analytical procedures. Low expected particle concentrations, the complexity of placental tissue and blood, and the risk of airborne or procedural contamination make sampling and sample preparation especially challenging. For engineered nanoparticles, aggregation, dissolution or other transformations during preparation must also be avoided.
MiNaPla addresses this analytical gap by developing contamination-controlled workflows for placenta, maternal blood and umbilical cord blood. The workflow covers representative sampling, matrix digestion, particle separation and preconcentration, chemical identification, particle sizing and quantification.
Complementary particle-based and elemental methods will be combined. Raman microspectroscopybased automated analysis using in-house made open source software TUM-ParticleTyper 2 polymer identification and characterization by particle number, size and shape. SEM and EDX provide high-resolution morphological and elemental information, while field-flow fractionation in combination with multidetectot platform, including online Raman supports size separation and physicochemical characterization of the smallest fractions. Atomic-spectrometric techniques are used to characterize engineered metal-based nanoparticles and trace metals.
MiNaPla also examines whether micro- and nanoplastics can act as carriers for metals, the so-called Trojan-horse phenomenon. The resulting validated methodology is intended to provide the reliable quantitative data required for future exposure and risk assessment during pregnancy.